Manal F. Abdelmalek
379 works · 48,457 citations · h-index 94
Top works
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Two Cases from the Spectrum of Nonalcoholic Steatohepatitis
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study
- Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver Disease
- Fructose consumption as a risk factor for non-alcoholic fatty liver disease
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
- Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
- A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
- Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease
- Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
- Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science